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Abstract
Background: Insulin resistance is associated with a proinflammatory state that promotes the development of
complications such as type 2 diabetes mellitus (T2DM) and atherosclerosis. The metabolic stimuli that initiate and
propagate proinflammatory cytokine production and the cellular origin of proinflammatory cytokines in insulin
resistance have not been fully elucidated. Circulating proinflammatory monocytes show signs of enhanced
inflammation in obese, insulin resistant subjects and are thus a potential source of proinflammatory cytokine
production. The specific, circulating metabolic factors that might stimulate monocyte inflammation in insulin
resistant subjects are poorly characterized. We have examined whether saturated nonesterified fatty acids (NEFA)
and insulin, which increase in concentration with developing insulin resistance, can trigger the production of
interleukin (IL)-6 and tumor necrosis factor (TNF)-a in human monocytes.
Methods: Messenger RNA and protein levels of the proinflammatory cytokines IL-6 and TNF-a were measured by
quantitative real-time PCR (qRT-PCR) and Luminex bioassays. Student’s t-test was used with a significance level of p
< 0.05 to determine significance between treatment groups.
Results: Esterification of palmitate with coenzyme A (CoA) was necessary, while b-oxidation and ceramide
biosynthesis were not required, for the induction of IL-6 and TNF-a in THP-1 monocytes. Monocytes incubated
with insulin and palmitate together produced more IL-6 mRNA and protein, and more TNF-a protein, compared to
monocytes incubated with palmitate alone. Incubation of monocytes with insulin alone did not affect the
production of IL-6 or TNF-a. Both PI3K-Akt and MEK/ERK signalling pathways are important for cytokine induction
by palmitate. MEK/ERK signalling is necessary for synergistic induction of IL-6 by palmitate and insulin.
Conclusions: High levels of saturated NEFA, such as palmitate, when combined with hyperinsulinemia, may
activate human monocytes to produce proinflammatory cytokines and support the development and propagation
of the subacute, chronic inflammatory state that is characteristic of insulin resistance. Results with inhibitors of b-
oxidation and ceramide biosynthesis pathways suggest that increased fatty acid flux through the glycerolipid
biosynthesis pathway may be involved in promoting proinflammatory cytokine production in monocytes.
Background
Insulin resistance is characterized by a myriad of meta-
bolic abnormalities, including hyperinsulinemia, hyper-
triglyceridemia, and an increased concentration of
NEFA in blood [1]. These dysmetabolic features, some-
times referred to as the metabolic syndrome, are
believed to contribute to the development of severe
complications of insulin resistance, such as T2DM and
atherosclerotic heart disease [2]. A common feature
observed in subjects with insulin resistance, T2DM, and
atherosclerotic heart disease is chronic, low-grade, sys-
temic inflammation [3,4] as evidenced by increases in
the concentration of proinflammatory cytokines (e.g.,
IL-6) in the blood, as well as increased concentrations
in the blood of surrogate markers for systemic IL-6
bioactivity, such as C-reactive protein. The metabolic
stimuli responsible for the increase in circulating proin-
flammatory cytokines and the cellular source of these
cytokines in insulin resistant subjects are not well
understood.
Adipose tissue has garnered a great deal of attention
as a potential source of elevated circulating inflamma-
tory cytokines in obesity and insulin resistance due to
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synthesize and secrete pro-inflammatory cytokines,
including TNF-a [5,6] and IL-6 [7]. Recently it was
shown that increased numbers of macrophages accumu-
late in adipose tissue in the obese [8], and these macro-
phages likely account for much of the inflammatory
cytokine secretion from adipose tissue. However, it was
reported that subcutaneous adipose tissue does not
release TNF-a in vivo, and likely accounts for only 15-
35% of systemic IL-6 release [7]. Also, Kern et al [9]
reported that IL-6 concentration in plasma was posi-
tively correlated with obesity and plasma NEFA levels,
but adipose tissue IL-6 production was not strongly
affected by obesity. Therefore, it is possible that the
bulk of the systemic proinflammatory cytokines in the
obese, insulin resistant state are derived from non-adi-
pose cellular and tissue sources.
Adipose tissue macrophages and macrophages of
atherosclerotic plaques presumably arise from circulat-
ing monocytes, a heterogeneous population of cells that
in humans can be divided into three discrete subsets
based on the expression level of cell surface markers
CD14, CD16, and CD64 [10]. CD14
hiCD16
- cells make
u pt h em a j o r i t yo fb l o o dm o n o c y t e s( ~ 8 0 % )a n dh a v ea
proinflammatory phenotype characterized by their ability
to produce abundant quantities of cytokines such as
TNF-a and IL-6 [11,12] when activated. An analogous
subset of proinflammatory monocytes has been
described in the mouse, albeit based on a distinct set of
cell surface markers [13]. Cells of this monocyte subset
in mice and humans also express high levels of recep-
tors for chemotactic peptides (e.g., CCR2, the receptor
for monocyte chemoattractant protein-1), allowing these
cells to efficiently respond to localized sites of inflam-
mation [12]. Indeed, it is the proinflammatory monocyte
subset that accumulates preferentially in obese adipose
tissue [14] and atherosclerotic plaques [15].
An emerging concept is that monocyte subsets may be
committed to a specific function before they localize to
sites of infection or tissue damage [12]. Evidence for
activation of circulating blood monocytes into a proin-
flammatory phenotype includes studies showing that cir-
culating monocytes isolated from obese human subjects
contained greater amounts of inflammatory cytokine
messenger RNA relative to monocytes isolated from
lean subjects [16], and induced hyperlipidemia in mice
is associated with expansion of the proinflammatory
monocyte subpopulation [15]. Additionally, lipid infu-
sion in humans acutely activates NFB, a proinflamma-
tory transcription factor, and stimulates the production
of macrophage migration inhibitory factor and reactive
oxygen species in circulating mononuclear leukocytes
[17]. Conversely, activation of peroxisome proliferator-
activated receptor g (PPAR g)h a sb e e ns h o w nt op r i m e
an anti-inflammatory subset of monocytes into an
enhanced anti-inflammatory monocyte phenotype [18].
NEFA have been demonstrated to induce inflamma-
tory cytokine production in mature macrophages [19].
However, the influence of NEFA on the inflammatory
phenotype of monocytes has not been explored. Further-
more, the combined impact of NEFA and hyperinsuline-
mia, which is particularly relevant to the insulin
resistant metabolic state [1], has not been explored for
its effect on monocyte inflammation. In this study, we
hypothesized that NEFA could act on human monocytes
to induce a proinflammatory phenotype as judged by
increased inflammatory cytokine production. We pro-
vide evidence that long-chain saturated fatty acids can
stimulate production and release of prototypical proin-
flammatory cytokines IL-6 and TNF- a in monocytes.
Furthermore, we demonstrate that insulin synergizes
with palmitate to induce higher levels of IL-6 in mono-
cytes than that induced by palmitate alone.
Methods
Materials
THP-1 human monocytic leukemia cells were obtained
from American Type Culture Collection (Manassas,
VA). Fatty acids (palmitate (C16:0), stearate (C18:0),
methylpalmitate, 2-bromopalmitate) and essentially fatty
acid-free, low endotoxin bovine serum albumin (BSA,
Sigma A8806) were obtained from Sigma-Aldrich (St.
Louis, MO). Regular human insulin (Humulin R100, Eli
Lilly, Indianapolis, IN) was obtained from the research
pharmacy at Arkansas Children’s Hospital. Inhibitors
were obtained from EMD Biosciences (San Diego, CA)
or Sigma-Aldrich.
Preparation of NEFA solutions
NEFA (50 mM) were dissolved in 0.1 M sodium hydro-
xide with brief heating at 70°C. NEFA-BSA complexes
were prepared by slowly adding 0.2 ml of NEFA solu-
tions to 0.8 ml of warm BSA (250 mg/ml in Dulbecco’s
phosphate buffered saline, pH 7.2) with stirring, to yield
a 10 mM NEFA-BSA stock solution with an approxi-
mate 3:1 NEFA:BSA ratio. Solutions were incubated at
37°C for 10-15 minutes prior to use, adjusted to pH 7.2,
and filter sterilized. Solutions were prepared fresh for
each experiment. Endotoxin levels were determined in
the 10 mM NEFA-BSA stock solution using a Pyrogent
Plus Gel Clot assay according to the manufacturer’s
instructions (Lonza Walkersville, Walkersville, MD) and
were less than 10 EU/ml.
Cell Culture Conditions and Experiments
THP-1 cells were cultured in RPMI 1640 (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal bovine serum
(Hyclone, Logan, UT), penicillin (100 U/ml)-streptomycin
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(Invitrogen), and 10 mM Hepes, pH 7.55 (Invitrogen).
Cells were maintained at a density between 1 - 8 × 10
5
cells/ml and used between passages 6 - 20.
Cells were seeded in serum free, supplemented RPMI
1640 containing 0.2% fatty acid free BSA at 5 × 10
5 cells
per ml/well in 24 well plates. Cells were rendered quies-
cent by overnight incubation in serum free media before
stimulation with NEFA. Media (1 mL) and cells were
collected at various times following stimulation with
NEFA. Wells were washed with 0.5 mL of Dulbecco’s
phosphate buffered saline and the wash was combined
with the cells/media. Cells were pelleted at 500 × g for
5 minutes at 4°C. Cytokine protein concentrations were
determined in media from cells stimulated for 12 or 24
hours with NEFA.
Human primary monocytes were isolated by adhesion
from the peripheral blood mononuclear cell (PBMC)
fraction of whole blood. Approximately 50 ml of hepari-
nized whole blood was obtained from healthy human
volunteers according to a research protocol approved by
the University of Arkansas Institutional Review Board.
Blood was layered over a Histopaque 1077 gradient
(Sigma-Aldrich) and centrifuged for 30 minutes at 400
g. PBMC were removed from the Histopaque-plasma
interface and were washed several times with a buffered
saline solution. PBMC (2 × 10
6) were plated in RPMI
1640 supplemented with 10% donor serum overnight.
The next morning, non-adherent cells were washed
from the plate and RPMI 1640 supplemented with 10%
FBS was added. Treatments with NEFA and/or insulin
were initiated approximately 8 hours later and were
allowed to proceed for 24 hours.
Western Blot Analysis of phosphorylated and total ERK1/2
and Akt
THP-1 cells were treated with insulin for 30 minutes,
harvested by centrifugation for 10 seconds in a micro-
centrifuge and washed one time with ice-cold phosphate
b u f f e r e ds a l i n e .T h ec e l lp e l l e tw a sl y s e di nS D Ss a m p l e
buffer (62.5 mM Tris-HCl (pH 6.8), 2% w/v sodium
lauryl sulphate, 10% glycerol, 50 mM dithiothreitol,
0.01% bromophenol blue) and heated. Extracts were
resolved on 10% SDS-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride membranes. Mem-
branes were incubated with polyclonal antibodies (Cell
Signaling Technology, Danvers, MA) directed against
human Akt, phosphorylated human Akt (phospho-
threonine 308), human ERK1/2, and phosphorylated
human ERK1/2 (ERK1 phospho-threonine 202, tyrosine
204, ERK2 phospho-threonine 185, phospho-tyrosine
187) and signals were developed according to the manu-
facturer’s protocol. Images were captured on a VersaDoc
5000 (Bio-Rad).
RNA Isolation and Real-Time Polymerase Chain Reaction
Cells were lysed in Tri Reagent (Sigma-Aldrich) and total
RNA was prepared according to the manufacturer’sp r o -
tocol. RNA (5 μg) was treated with DNase I (Promega,
Madison, WI) according to the manufacturer’sp r o t o c o l .
DNase reactions were diluted 10-fold with nuclease free
water (Invitrogen) and were concentrated in YM-100
spin columns (Millipore). RNA (0.5 μg) was reverse-tran-
scribed using iScript (Bio-Rad, Hercules, CA) according
to the manufacturer’s protocol. Quantitative PCR was
carried out in an Applied Biosystems Prism® 7900HT
Sequence Detection System (California) using SYBR®
Green Supermix with ROX (Bio-Rad). Reactions con-
tained 25 ng of cDNA and 0.25 μM forward and reverse
primers. Primers were designed using Beacon Designer
3.0 (Premier Biosoft Intl., Palo Alto, CA) and were
ordered from Sigma-Aldrich at standard desalted purity.
Pooled THP-1 cDNA, from cells that were treated with 1
μg/ml bacterial lipopolysaccharide to induce cytokine
production, was serially diluted from 25 ng to 8 pg to
construct a standard curve for all genes of interest and
for reference genes. Gene expression was normalized for
GAPDH expression to accurately reflect input cDNA
quantity. Primer sequences were GAPDH forward: 5’
ggagtccactggcgtctt 3’, GAPDH reverse: 5’ aggctgttgtca-
tacttctcat 3’,I L - 6f o r w a r d :5 ’ ttcggtccagttgccttctc 3’,I L - 6
reverse: 5’ gaggtgagtggctgtctgtg 3’,T N F - a forward: 5’
ctccaggcggtgccttgttc 3’,T N F - a reverse: 5’ caggcagaa-
gagcgtggtg 3’.
Determination of Secreted IL-6 and TNF-a protein
IL-6 and TNF-a were measured simultaneously in con-
ditioned media prepared from THP-1 monocytes using
a high sensitivity human cytokine multiplex immunoas-
s a y( L i n c o ,S t .C h a r l e s ,M O ) .A s s a y sw e r er u no na
Luminex® 100™ Bioanalyzer (Luminex Corp., Austin,
TX) according to the kit manufacturer’s instructions.
Kits contained distinct groups of microspheres (each
group bearing unique fluorescence intensity and a speci-
fic cytokine antibody), biotinylated cytokine antibodies,
and phycoerythrin conjugated streptavidin. Conditioned
media samples were incubated with antibody-coated
microspheres, which bind to specific cytokines present
in the media. Next, microsphere-cytokine complexes
were washed and incubated with biotinylated cytokine
antibodies, which bind to cytokines present on the
microspheres. A final incubation was performed in
which phycoerythrin-labeled streptavidin was allowed to
bind to biotinylated IL-6 or TNF-a antibodies present
on microspheres. Microspheres were then loaded into a
Luminex® 100™ Bioanalyzer, which quantifies the
amount of phycoerythrin fluorescence present on each
of the distinct microsphere groups. At least 50 indivi-
dual microspheres were counted for each cytokine, and
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quent calculations.
Statistical Analysis
Data are represented as the mean ± standard error (SE)
for three to four independent measurements. Student’s
two-tailed unpaired t-test was used for comparisons
between groups with significance set at P < 0.05.
Results
Saturated long-chain NEFA stimulate IL-6 and TNF-a
production in THP-1 cells
THP-1 monocytic cells have been used extensively as a
model of primary human monocytes, have been shown
to closely mimic primary human monocytes in their
production of TNF-a in response to lipopolysaccharide
[20] and have been utilized in diabetes-related studies,
such as studies to investigate the production of IL-6 by
monocytes in hyperglycemic conditions [21]. Therefore,
we chose to utilize the THP-1 cell line to study the pos-
sible role of NEFA in the induction of inflammation in
human monocytes.
Normal circulating NEFA concentrations are less than
700 μM in the post-absorptive state [22], therefore, we
chose to use 500 μM as an initial concentration of
NEFA to determine the effect of long-chain saturated
NEFA on inflammatory cytokine production in THP-1
monocytes. THP-1 cells that had been incubated for 24
hours with 500 μM palmitate, a 16 carbon saturated
fatty acid, secreted significantly more IL-6 and TNF-a
into the media compared to media from control cells
incubated with BSA lacking bound NEFA (Figure 1A).
Stearate, an 18 carbon saturated fatty acid, also stimu-
lated IL-6 release, but did not increase the amount of
TNF-a released over that released from untreated or
BSA-treated control cells (Figure 1A).
Consistent with the increase in IL-6 protein produc-
tion elicited by palmitate and stearate, IL-6 mRNA
expression was increased significantly in THP-1 cells
incubated for 12 hours with 500 μM palmitate (~50-fold
induction) or stearate (~20-fold induction) compared to
cells incubated with BSA alone (Figure 1B). While pal-
mitate, but not stearate, stimulated TNF-a protein
synthesis and release by THP-1 cells, both NEFA signifi-
cantly increased TNF-a mRNA expression compared to
cells treated with BSA alone (Figure 1B).
The concentration of NEFA in plasma can vary over a
wide range depending on feeding status and sensitivity
to the anti-lipolytic effects of insulin. To understand
how IL-6 and TNF-a could be regulated by a range of
physiological concentrations of NEFA in monocytes,
THP-1 cells were treated with palmitate concentrations
ranging from 50 μMt o5 0 0μM. IL-6 and TNF- a
mRNA expression was significantly induced by
concentrations of palmitate ≥ 125 μM (Figure 1C), indi-
cating that inflammatory cytokine production in mono-
cytes may be significantly increased by conditions such
as insulin resistance, where monocytes would be
exposed to chronically elevated plasma NEFA
concentrations.
Palmitate metabolism is required for induction of IL-6
and TNF-a in THP-1 cells
Two non-metabolizable analogs of palmitic acid, methyl
palmitate and 2-bromopalmitic acid (Figure 2A), were
utilized to determine whether intracellular metabolism
of palmitate was required for the induction of IL-6 and
TNF-a in monocytes. The esterification of palmitate by
a methyl group in methyl palmitate prevents activation
of this molecule by CoA, and abrogates downstream
metabolism of the fatty acid, whereas 2-bromopalmitate
can be activated by CoA, but cannot be further metabo-
lized by b-oxidation or esterification with glycerol to
form glycerolipids [23]. However, 2-bromopalmitate has
been shown to occupy the same binding sites within
albumin and fatty acid binding proteins, with a similar
binding affinity, as unmodified palmitate [24]. Incuba-
tion with 250 μM palmitate for 12 hours stimulated
monocytes to produce IL-6 and TNF-a mRNAs at levels
>20-fold and >7-fold greater, respectively, than cells sti-
mulated with BSA lacking bound NEFA (Figure 2B). In
contrast, cells treated with either of the non-metaboliz-
able palmitate analogs, at the same concentration used
for palmitate, produced amounts of IL-6 and TNF-a
mRNA that were not significantly increased compared
to cells treated with BSA (Figure 2B), suggesting that
palmitate metabolism via the glycerolipid biosynthetic
pathway, ceramide biosynthetic pathway, or b-oxidation
pathway is necessary for the induction of IL-6 and TNF-
a in monocytes. Consistent with these results, we
observed that triacsin C, a competitive inhibitor of fatty
acid binding to long-chain fatty acyl CoA synthetases,
significantly inhibited the induction of IL-6 and TNF-a
mRNAs in cells incubated with palmitate (Figure 2C).
To determine which intracellular fatty acid metabolic
pathways might be involved in the induction of IL-6 and
TNF-a by NEFA, THP-1 cells were treated with inhibi-
tors of fatty acid oxidation or ceramide biosynthesis
prior to incubation with palmitate and the production
of IL-6 and TNF-a mRNAs measured. Etomoxir is an
irreversible inhibitor of carnitine palmitoyltransferase I
(CPT I), the rate-limiting enzyme for fatty acyl-CoA
uptake into mitochondria, where b-oxidation takes
place. Pre-treatment of THP-1 cells with 5 μM etomoxir
significantly increased IL-6 mRNA production, but not
that of TNF-a, in response to palmitate when compared
to cells incubated with palmitate in the absence of eto-
moxir (46-fold IL-6 induction by palmitate + etomoxir
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p < 0.05).
Ceramides have been implicated in the induction of
inflammatory and cell death signalling pathways in
numerous cell types [25]. THP-1 cells were pre-treated
with 50 nM myriocin, an inhibitor of serine palmitoyl-
transferase, the rate-limiting first step in the de novo
ceramide biosynthetic pathway, prior to incubation with
palmitate. IL-6 or TNF- a mRNA induction by palmi-
tate was not affected by myriocin (Figure 3B). Together,
these results seem to rule out the b-oxidation and cera-
mide pathways in monocytes as having a role in the
induction of IL-6 and TNF-a by palmitate, thus indir-
ectly implicating components of the glycerolipid biosyn-
thetic pathway in mediating the induction of IL-6 and
TNF-a by palmitate.
Insulin synergizes with palmitate to induce IL-6 mRNA
production
Insulin is an important physiological regulator of intra-
cellular fatty acid metabolism by inhibiting fatty acid
oxidation and promoting the synthesis and storage of
glycerolipids in adipocytes and other insulin-responsive
cells. Therefore, if the glycerolipid biosynthetic pathway
Figure 1 Saturated NEFA stimulate IL-6 and TNF-a production. A, IL-6 and TNF-a concentration in 24-hour conditioned media from THP-1
cells that were untreated or stimulated with 500 μM palmitate or stearate, or NEFA- and endotoxin-free BSA. B, IL-6 and TNF-a mRNA expression
in THP-1 cells stimulated as in A for 12 hours. C, IL-6 and TNF-a mRNA expression in THP-1 cells stimulated with the indicated concentrations of
palmitate for 12 hours. Values are means ± SE (n = 3-4). *, p < 0.05, # p < 0.01 versus BSA treatment, ND - below the limit of detection.
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NEFA, insulin may further augment IL-6 production in
the presence of excess NEFA. Peripheral blood mono-
cytes would encounter conditions of hyperinsulinemia
and above normal concentrations of fatty acids in insu-
lin resistant individuals; therefore, this metabolic situa-
tion may contribute the proinflammatory state that is
associated with insulin resistance in vivo. THP-1 cells
were incubated with palmitate ± insulin, or BSA ± insu-
lin, and cellular IL-6 and TNF-a mRNAs measured. In
the presence of insulin, palmitate induced significantly
more IL-6 mRNA as compared to cells incubated with
palmitate alone (52-fold IL-6 induction palmitate +
insulin vs. 29-fold IL-6 induction palmitate only, p <
0.05, Figure 4A), while insulin had no effect on IL-6
production in cells incubated with BSA. Insulin had no
effect on TNF-a production in cells incubated with pal-
mitate or BSA (Figure 4A). IL-6 and TNF-a protein
secretion was measured in THP-1 cells incubated with
palmitate alone, or palmitate plus varying concentrations
of insulin chosen to approximate normal physiologic
and hyperinsulinemic conditions. THP-1 cells incubated
with palmitate plus insulin at 1 ng/ml and 5 ng/ml con-
centrations produced significantly more IL-6 protein
than cells incubated with palmitate only (Figure 4B),
consistent with earlier observations for IL-6 mRNA and
demonstrating that physiological concentrations of insu-
lin can synergize with physiological concentrations of
palmitate to induce IL-6. In contrast to results obtained
with TNF-a mRNA, TNF-a protein secretion from
Figure 2 Palmitate metabolism is required for the induction of IL-6 and TNF-a. A, Chemical structure of palmitic acid and non-
metabolizable palmitic acid analogs methylpalmitate (MP) and 2-bromopalmitate (2-BP). B, IL-6 and TNF-a mRNA expression in THP-1 cells
stimulated for 12 hours with palmitate (250 μM) or equivalent concentrations of MP or 2-BP. C, IL-6 and TNF-a mRNA expression in THP-1 cells
stimulated with palmitate in the presence of vehicle (DMSO) or an inhibitor of long chain fatty acyl CoA synthetase (triacsin C, 1 μM). Values are
means ± SE (n = 3). *, p < 0.05, #, p < 0.01 versus BSA.
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and palmitate compared to those incubated with palmi-
tate only (Figure 4B).
Insulin binding to the insulin receptor engages two
primary signal transduction pathways, the mitogen acti-
vated protein kinase (MAPK)/extracellular regulated
kinase (ERK) kinase (MEK) - ERK pathway and phos-
phatidylinositide 3-kinase (PI3K) - Akt pathway, in insu-
lin responsive cells [26]. To determine whether insulin
signal transduction pathways were activated in THP-1
cells and whether MEK or PI3K inhibitors were effective
at inhibiting insulin signal transduction, THP-1 cells
were pre-incubated with vehicle (DMSO), a MEK inhibi-
tor (U0126), or a PI3K inhibitor (LY294002) and then
were either left untreated or were stimulated for 30
minutes with insulin (5 ng/ml). Cell extracts were ana-
lyzed by Western blot using antibodies directed against
total ERK1/2 (i.e., phosphorylated and unphosphorylated
forms), phosphorylated ERK1/2, total Akt, and phos-
phorylated Akt. Insulin stimulated phosphorylation of
ERK1/2 and Akt was significantly increased over basal
levels in the presence of DMSO (Figure 5A, B). U0126,
which inhibits MEK1/2, the kinase responsible for phos-
phorylating ERK1/2, reduced ERK1/2 phosphorylation
to undetectable levels in both basal and insulin-stimu-
lated cells, while the PI3K inhibitor LY294002 appeared
to slightly increase basal and insulin-stimulated ERK1/2
phosphorylation (Figure 5A). LY294002, an inhibitor of
PI3K, the kinase responsible for phosphorylating threo-
nine 308 within Akt, appeared to completely eliminate
basal Akt phosphorylation and partially inhibited insu-
lin-stimulated phosphorylation of Akt (Figure 5B).
Inhibition of MEK1/2 or PI3K significantly reduced IL-
6 mRNA induction by palmitate ± insulin by approxi-
mately 90% (Figure 5C) when compared to DMSO trea-
ted cells. However, only the MEK1/2 inhibitor reduced
Figure 3 Mitochondrial oxidation or ceramide generation is not necessary for induction of IL-6 and TNF-a by palmitate. IL-6 and TNF-a
mRNA expression in THP-1 cells treated with A, etomoxir (5 μM), an inhibitor of mitochondrial fatty-acyl CoA uptake, or B, myriocin, an inhibitor
of ceramide biosynthesis, for 1 hour followed by incubation with palmitate (250 μM) for 12 hours. Values are means ± SE (n = 3). #, p < 0.01
versus BSA.
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such that IL-6 production in cells treated with palmitate
+ insulin was not significantly greater than in cells trea-
ted only with palmitate (Figure 5C).
Inhibition of MEK1/2 had little effect on TNF- a pro-
duction in cells treated with palmitate ± insulin, however,
PI3K inhibition with LY294002 significantly increased
TNF-a production in palmitate-treated cells versus cells
treated with palmitate + vehicle (DMSO) (Figure 5D).
Interestingly, this effect of LY294002 was partially
reversed by insulin co-treatment, perhaps due to the
incomplete inhibition of Akt phosphorylation that was
achieved in these cells as demonstrated in Figure 5B.
Insulin synergizes with palmitate to induce IL-6 mRNA in
primary human monocytes
Although THP-1 cells have been used extensively as a
model for primary human monocytes, in some instances
the responses exhibited by THP-1 cells and primary cells
do not correspond. To determine whether primary human
monocytes produce IL-6 and TNF-a in response to incu-
bation with saturated NEFA, and whether saturated NEFA
and insulin synergize to induce IL-6 in these cells, primary
monocytes isolated from the PBMC fraction of whole
blood were exposed to palmitate ± insulin for 24 hours
and the production of IL-6 and TNF-a mRNA determined
by qRT-PCR. Similar to our observations in THP-1 cells,
Figure 4 Synergistic induction of IL-6 by palmitate and insulin. A, IL-6 and TNF-a mRNA expression in THP-1 cells stimulated for 30 minutes
with 5 ng/ml insulin (+ insulin) or vehicle (- insulin) and then stimulated with palmitate (250 μM) or fatty acid-free BSA, for an additional 12
hours. B, IL-6 and TNF-a concentration in media from THP-1 cells stimulated for 30 minutes with the indicated concentrations of insulin and
then stimulated with palmitate (125 μM) for 24 hours. Values are means ± SE (n = 3). *, p < 0.05, #, p < 0.01 versus (- insulin).
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and TNF-a mRNA expression (Figure 6A, B). Further-
more, insulin, when used at concentrations similar to
those used in THP-1 cells, augmented the production of
IL-6 in response to palmitate to a similar degree as in
THP-1 cells (Figure 6A), while TNF-a mRNA levels were
not affected by the presence of insulin (Figure 6B).
Discussion
These studies are the first to demonstrate that human
monocytes synthesize and secrete IL-6 and TNF-a in
response to saturated NEFA. Our results are consistent
with the observations of others that saturated NEFA can
induce an inflammatory response in a variety of other
cell types, including endothelial cells [27], adipocytes
[28], myotubes [29], and macrophages [30,31]. NEFA
have recently been shown to increase reactive oxygen
species and the expression of b2 integrin in monocytes,
and increase monocyte adhesion to endothelial cells
[32]. Our results suggest that circulating blood mono-
cytes in vivo may respond to increases in saturated
NEFA concentrations in insulin resistant conditions by
producing high levels of IL-6, which could prime these
cells to generate a robust local or systemic inflammatory
response and contribute to the development of compli-
cations such as T2DM and atherosclerosis.
Regarding the molecular mechanism of inflammatory
cytokine induction by saturated NEFA, some studies
Figure 5 MEK/ERK and PI3K/Akt signaling pathways regulate IL-6 production. Total and phosphorylated ERK1/2 (A) or total and
phosphorylated Akt (B) were analyzed by Western blotting of cellular extracts from control (-) and insulin-stimulated (+) THP-1 cells that were
pre-treated with vehicle (DMSO), MEK1/2 inhibitor (U0126), or PI3K inhibitor (LY294002). Western blots representative of three independent
experiments are shown. IL-6 (C) and TNF-a (D) mRNA expression determined by qRT-PCR in THP-1 cells treated for 1 hour as in (A) followed by
stimulation for 30 minutes with 5 ng/ml insulin (+ insulin) or vehicle (- insulin), in the presence of vehicle (DMSO), and then stimulated with
palmitate (250 μM) or fatty acid-free BSA, for an additional 24 hours. Values are means ± SE (n = 3) expressed relative to the expression level of
these cytokines in BSA-treated cells.
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Page 9 of 13have demonstrated that saturated NEFA induce IL-6 via
TLR2 or TLR4 receptors in myocytes, macrophages, and
adipocytes [19,33]. However, other studies have demon-
strated that NEFA metabolism was required for the
induction of inflammatory cytokines in endothelial cells
[27]. Therefore, it appears that saturated NEFA are
potent inducers of inflammation in diverse cell types,
but that the molecular mechanisms for cytokine induc-
tion vary according to cell type. Our results suggest that
monocytes are more like endothelial cells in their
inflammatory response to saturated NEFA, in that fatty
acid metabolism appears to be required for cytokine
induction (Figure 2B). In fact, our results with the b-oxi-
dation inhibitor etomoxir showed that inhibition of b-
oxidation of palmitate enhanced IL-6 induction in
monocytes. This raises the interesting possibility that
interference with b-oxidation may increase the intracel-
lular concentration of palmitoyl-CoA available for use
by other metabolic pathways that can stimulate IL-6
mRNA production. A candidate for this IL-6 inducing
pathway is the triglyceride synthesis pathway, which
contains several intermediates such as lysophosphatidic
acid, phosphatidic acid, and diacylglycerol, which have
all been shown to have inflammation-promoting proper-
ties in a variety of cells [34,35]. Consistent with our stu-
dies, Staiger et al.[ 2 7 ]s h o w e dt h a tn e i t h e r
mitochondrial b-oxidation of fatty acids or ceramide
biosynthesis was involved in IL-6 induction by palmitate
in endothelial cells. However, Schwartz et al.[ 3 6 ]
recently reported that palmitate metabolism to ceramide
was necessary for amplification of LPS-induced
inflammation in human monocytes. Direct measurement
of glycerolipid intermediates in monocytes incubated
with NEFA will be required to definitively support the
hypothesis that increased fatty acid flux through the tri-
glyceride synthesis pathway is involved in the induction
of IL-6, TNF- a, and perhaps other cytokines whose
levels increase in insulin resistant conditions.
Our results demonstrated that hyperinsulinemia,
coupled with elevated levels of NEFA, generated higher
levels of IL-6 production in monocytes compared to the
IL-6 response to NEFA alone. The marked increase in
IL-6 production observed between 0, 1 and 5 ng/ml
concentrations of insulin demonstrates that even modest
increases in insulin levels within the range encompass-
ing fasting and post-prandial insulin levels observed in
insulin resistant subjects, along with physiological levels
of NEFA, can dramatically affect IL-6 production. This
result is particularly relevant in the context of the meta-
bolic status of the obese, insulin resistant individual,
where fasting levels of NEFA and insulin are likely to be
chronically elevated [1]. Numerous studies have shown
that IL-6 concentration is increased in the circulation of
obese, insulin resistant humans [37]. Kern et al.[ 9 ]
implicated NEFA and insulin in the regulation of circu-
lating IL-6 by demonstrating that circulating IL-6 levels
showed a strong positive correlation with serum NEFA
levels and a strong negative correlation with insulin sen-
sitivity, which varies inversely with insulin levels.
Although IL-6 plays a deleterious role in the develop-
ment of coronary artery disease and is an early indicator
of incipient type 2 diabetes mellitus [38-40], some
Figure 6 Synergistic induction of IL-6 mRNA in primary human monocytes. Monocytes isolated by adherence from human PBMC fraction
of whole blood were incubated for 30 minutes with varying concentrations of insulin, followed by 24 hour incubation with 500 μM palmitate or
BSA. IL-6 (A) and TNF-a (B) mRNAs were determined by qRT-PCR. Values are means ± SE (n = 3) expressed relative to the expression level of
these cytokines in BSA-treated cells. *, p < 0.05 versus (- insulin).
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Page 10 of 13studies suggest that IL-6 may have beneficial effects in
the resolution of inflammation and improvement of
insulin sensitivity following exercise [39,41,42]. Some
positive effects of IL-6 have been postulated to occur via
activation of adenosine monophosphate-activated pro-
tein kinase (AMPK) [43], an enzyme whose activation
promotes ATP production via fatty acid oxidation.
Thus, increased IL-6 production from exercised muscle
may serve as a local signal to increase energy production
via fatty acid oxidation, whereas increased IL-6 produc-
tion from peripheral monocytes exposed to elevated
concentrations of fatty acids may serve as a systemic sig-
nal to inhibit fatty acid production and stimulate fatty
acid oxidation. Indeed, a recent study demonstrated that
mice lacking IL-6 were prone to develop hepatosteatosis,
liver inflammation and insulin resistance when com-
pared to wild-type mice [44], supporting a role for IL-6
in the suppression of inflammation and regulation of
lipid homeostasis and metabolism in vivo.
Insulin signaling in the monocyte/macrophage lineage
m a yp l a yav i t a lr o l ei nt h er e g u l a t i o no fl o c a la n ds y s -
temic inflammation. In mice, selective removal of insulin
receptor expression in the myeloid lineage, which
includes monocytes/macrophages and granulocytes,
abolished LPS-elicited IL-6 production in macrophages,
while minimally affecting TNF-a or MCP-1 production
[45]. A recent report demonstrated that mice lacking
insulin receptor expression in the myeloid lineage were
protected from insulin resistance when fed a high-fat
diet, possibly due to reduced systemic inflammation and
decreased monocyte/macrophage infiltration of white
a d i p o s et i s s u e[ 4 6 ] .E v i d e n c ef r o min vitro studies also
supports a role for insulin in the regulation of proin-
flammatory cytokine production in macrophages. LPS
treatment of monocytes generated a greater IL-6
response when co-administered with insulin compared
to the IL-6 response to LPS treatment alone [47].
Therefore, our results and the results of others support
the hypothesis that IL-6 induction by NEFA in mono-
cytes and macrophages is regulated by insulin.
It may seem counterintuitive to postulate that some of
the cellular effects of insulin could be preserved in the
face of insulin resistance. However, insulin resistance
specifically refers to the inability of insulin to promote
cellular glucose uptake, which is mediated primarily via
the phosphatidylinositol-3 kinase (PI3K) signalling path-
way downstream of the insulin receptor. It has been
documented that the PI3K pathway appears to be selec-
tively inhibited in insulin resistant states, whereas
another major signalling pathway downstream of the
insulin receptor, the Ras-Raf-MAPK signaling pathway,
remains sensitive to insulin even when metabolic effects
of insulin are blunted in some cell types [48,49]. Our
results demonstrate that both PI3K-Akt and MAPK sig-
nalling pathways are utilized by palmitate to produce
IL-6 and TNF-a. However, the MAPK signalling path-
way seems to be more important for the synergistic
induction of IL-6 by palmitate and insulin.
Some limitations of this study warrant discussion.
THP-1 cells used in this study are transformed cells that
were derived from an acute myelogenous leukemia
patient. Although the primary findings obtained in
THP-1 cells were validated in primary human mono-
cytes ex vivo, further studies are necessary to determine
whether our findings in vitro can be translated to in
vivo conditions. Insulin resistance results in numerous
metabolic abnormalities in addition to increased NEFA
concentrations and hyperinsulinemia that were modelled
in isolation in this study, therefore further in vitro stu-
dies will be required to understand how the complex
metabolic alterations of insulin resistance regulate
inflammation in human monocytes.
Conclusions
The proinflammatory subset of monocytes has the capa-
city to produce large quantities of inflammatory cyto-
k i n e ss u c ha sI L - 6 ,a n dt h i ss u b s e to fm o n o c y t e s
accumulates in adipose tissue and artery walls, where
they are believed to initiate and propagate disease pro-
cesses. Thus, chronic activation of monocyte IL-6 pro-
duction by high levels of fatty acids and
hyperinsulinemia in insulin resistant subjects could pro-
duce local and systemic inflammation. Local production
of IL-6 at sites of monocyte infiltration could initiate
insulin resistance in adipose tissue, or produce rupture-
prone atherosclerotic plaques in arteries. Systemic pro-
duction of IL-6 could induce the acute phase response
in liver, which entails the production of pro-coagulant
factors such as plasminogen activator inhibitor 1 and
antimicrobials such as C-reactive protein, whose
increased concentrations have been associated with car-
diovascular disease [50,51]. Alternatively, monocyte pro-
duction of IL-6 may be beneficial, serving to suppress
inflammatory stress induced by NEFA and other meta-
bolites. A better understanding of the molecular
mechanisms utilized by saturated NEFA and insulin to
regulate IL-6 production in proinflammatory monocytes
could identify targets for novel anti-inflammatory mole-
cules that could reduce the incidence of complications
from insulin resistance.
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